SK3532000A3 - Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof - Google Patents

Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof Download PDF

Info

Publication number
SK3532000A3
SK3532000A3 SK353-2000A SK3532000A SK3532000A3 SK 3532000 A3 SK3532000 A3 SK 3532000A3 SK 3532000 A SK3532000 A SK 3532000A SK 3532000 A3 SK3532000 A3 SK 3532000A3
Authority
SK
Slovakia
Prior art keywords
ligand
seq
kay
kay ligand
sequence
Prior art date
Application number
SK353-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Jurg Tschopp
Original Assignee
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech R & D Sa filed Critical Apotech R & D Sa
Publication of SK3532000A3 publication Critical patent/SK3532000A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SK353-2000A 1997-09-12 1998-09-11 Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof SK3532000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Publications (1)

Publication Number Publication Date
SK3532000A3 true SK3532000A3 (en) 2001-12-03

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
SK353-2000A SK3532000A3 (en) 1997-09-12 1998-09-11 Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999026463A2 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligand tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
KR100834809B1 (ko) 1999-01-25 2008-06-05 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ, 관련 차단제 및 면역 반응에서 ｂ 세포와면역글로불린을 촉진 및 억제하는데에 있어서 이들의 용도
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
RS51157B (sr) * 1999-08-17 2010-10-31 Biogen Idec Ma Inc. Baff receptor (bcma), imunoregulatorni agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (fr) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Polypeptide heterologue de la famille tnf
ES2267593T3 (es) 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
DE60128216T2 (de) 2000-05-12 2008-01-10 Amgen Inc., Thousand Oaks Polypeptide zum Hemmen der April-vermittelten Proliferation von B- und T- Zellen
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
CA2419661A1 (fr) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ATE375361T1 (de) 2001-05-11 2007-10-15 Amgen Inc Peptide und verwandte moleküle, die an tall-1 binden
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
KR20070001880A (ko) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
WO2005075511A1 (fr) * 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
AU2005294666A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
EP1836224A1 (fr) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Polypeptides de bcma et leur utilisation
MX2008001661A (es) 2005-08-09 2008-04-07 Ares Trading Sa Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion del activador de transmembrana o interactor del ligando de ciclofilina de modulacion de calcio-ig.
EP1922079A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
CA2772929A1 (fr) 2009-09-03 2011-03-11 Genentech, Inc. Procedes pour traiter, diagnostiquer, et surveiller la polyarthrite rhumatoide
CA2827859A1 (fr) 2011-02-28 2012-09-07 Genentech, Inc. Marqueurs biologiques et procedes de prediction de reponse a des antagonistes de lymphocytes b
WO2014122143A1 (fr) 2013-02-05 2014-08-14 Engmab Ag Procédé de sélection d'anticorps anti-bcma
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf

Also Published As

Publication number Publication date
TR200000654T2 (tr) 2000-07-21
HUP0004034A2 (en) 2001-03-28
WO1999012964A3 (fr) 1999-05-27
EP1012270A2 (fr) 2000-06-28
NO20001240L (no) 2000-05-10
CN1269832A (zh) 2000-10-11
CA2303424A1 (fr) 1999-03-18
AU9315298A (en) 1999-03-29
BR9812433A (pt) 2000-09-26
JP2001515711A (ja) 2001-09-25
PL339740A1 (en) 2001-01-02
IL134480A0 (en) 2001-04-30
IS5375A (is) 2000-02-11
NO20001240D0 (no) 2000-03-09
KR20010023892A (ko) 2001-03-26
HUP0004034A3 (en) 2002-08-28
EA200000311A1 (ru) 2000-10-30
EE200000148A (et) 2001-02-15
WO1999012964A2 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
SK3532000A3 (en) Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
US7695934B2 (en) Tumor necrosis factor related ligand
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
SK3542000A3 (en) Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
AU774498B2 (en) A tumor necrosis factor related ligand
CZ2000867A3 (cs) Sekvence DNA kódující ligand Kay, způsob přípravy ligandu Kay a farmaceutický přípravek obsahující tento ligand
MXPA99001342A (en) A tumor necrosis factor related ligand